Celgene reports Phase Ib Crohn's data

Celgene Corp. (NASDAQ:CELG) said 12-week interim data showed that oral mongersen ( GED-0301) led to endoscopic improvement and clinical response and remission in "a proportion of patients" across all treatment groups in the Phase Ib CD-001 study to treat active Crohn's disease.

According to ClinicalTrials.gov, three Phase III studies of the candidate are ongoing. One trial's primary endpoint is clinical remission at week four, while another study is evaluating change from baseline in SMAD family member 7 ( MADH7; SMAD7) expression in the intestinal mucosa. The third is a long-term safety study. ...